The new guideline recommends a patient-centered approach to diagnosing Alzheimer's disease, involving goal-setting, risk profiling, symptom description, cognitive testing, and diagnostic imaging. A care partner's involvement is crucial, especially for patients with compromised cognition.
The Alzheimer's Association redefines clinical meaningfulness, finding modest yet significant benefits from approved treatments that expand over time. Combination therapies are expected to provide more substantial benefits moving forward.
A three-year study of over 2,200 older adults found daily multivitamin-mineral supplementation resulted in a statistically significant cognitive benefit. The Alzheimer's Association emphasizes the need for independent confirmatory studies to establish effectiveness.
Research found associations between COVID-19 and persistent cognitive deficits, including brain fog, loss of smell, and acceleration of Alzheimer's disease pathology. Biological markers of brain injury and neuroinflammation correlate with neurological symptoms in COVID-19 patients.
The National Institute on Aging (NIA) has launched Outreach Pro, a new online tool to help increase awareness and participation in Alzheimer's clinical trials among traditionally underrepresented communities. The tool allows researchers to create customizable recruiting materials with an emphasis on reaching diverse populations.
Research reveals that transgender and gender nonbinary adults experience higher rates of subjective cognitive decline, depression, and functional limitations compared to cisgender adults. The findings highlight the need for culturally competent healthcare services to address the unique needs of aging transgender individuals.
Researchers estimate global dementia cases will nearly triple to 152 million by 2050 due to a combination of factors, including aging population growth and increasing risk factors like obesity and heart health issues. The highest increase is projected in eastern sub-Saharan Africa, North Africa, and the Middle East.
Reducing fine particulates and traffic-related pollutants in the air may lower dementia risk by 14-26% and slow cognitive decline. Studies found that older women living in cleaner areas experienced fewer cases of dementia and slower brain function deterioration.
The Alzheimer's Association, Global Brain Health Institute, and Alzheimer's Society have partnered to fund 23 small-scale pilot projects addressing global challenges in dementia. These projects focus on innovative approaches to awareness, diagnosis, treatment, and care for individuals with Alzheimer's disease and other dementias.
Researchers have identified measurable Alzheimer's risk factors in adolescents and young adults, emphasizing the need for early interventions targeting heart health and education. Studies found that high blood pressure, diabetes, and poor educational quality are associated with worse late-life cognition, particularly in African Americans.
A blood test for Alzheimer's disease has shown high accuracy in detecting the disease, with levels of p-tau217 increasing seven-fold in individuals with Alzheimer's. The test detected tau brain changes 20 years before cognitive impairment in those with a genetic predisposition.
Research reveals flu vaccinations can reduce Alzheimer's incidence by up to 17%, with pneumococcal vaccination showing a similar protective effect. Vaccination also found to reduce mortality in people with dementia.
Researchers are studying brain aging and dementia in 500 individuals born in 1946, using detailed assessments and brain scans to identify risk factors. The goal is to develop better preventative health strategies and improve clinical trials.
The Alzheimer's Association has received a $1.34 million dollar grant from the National Institutes of Health to strengthen psychosocial research in dementia care. The LINC-AD project aims to develop evidence-based measures and tools to improve quality of life for people with dementia and their caregivers.
The Global Brain Health Leader Awards announce initiatives addressing dementia prevention, care and support in 14 countries. The awards span $675,000 funding to drive projects and research.
The Alzheimer's Association is investing in three research projects to develop new treatments and protect against Alzheimer's disease. Researchers are exploring a gene that may reduce risk, preventing nerve cell death, and using ultrasound to stimulate brain activity for improved memory.
A nationwide study found that amyloid PET imaging significantly influenced clinical management of patients with mild cognitive impairment and dementia. The technique altered diagnoses and treatment plans in nearly two-thirds of cases, more than double predictions.
The Alzheimer's Association has awarded funding for the SPRINT MIND 2.0 Study, which aims to investigate intensive blood pressure treatment and its impact on reducing dementia risk. The study will continue to follow up trial participants with two years of additional assessment.
The Alzheimer's Association has awarded six international researchers with $1 million each over two years to explore innovative treatments for early-stage Alzheimer's disease. The goal is to discover effective drugs that can rejuvenate brain cells and slow or halt the progression of the disease.
The SPRINT MIND Study found significant reductions in the risk of mild cognitive impairment (MCI) and combined risk of MCI plus all-cause dementia through intensive blood pressure control. This study provides the strongest evidence to date on reducing MCI and dementia risk through cardiovascular disease treatment.
A new study highlights the need for effective treatments for non-cognitive symptoms of dementia, such as agitation and behavioral changes. Researchers found that synthetic cannabinoid treatment, like nabilone, may be an effective option for treating agitation in people with Alzheimer's disease.
Studies investigate how changes in gut bacteria and lipid metabolism may influence brain health and cognitive decline. Research suggests that altered plasmalogens production by the liver may result in reduced availability of critical lipids to the brain, contributing to impaired cognitive function and neurodegeneration in Alzheimer's.
A virtual reality learning program is being used to prepare high school students to interact with older adults with Alzheimer's disease. The program aims to increase empathy and reduce negative attitudes towards people with dementia.
The new National Strategy for Recruitment and Participation in Alzheimer's Disease Clinical Research aims to increase enrollment of underrepresented groups, including African Americans. The strategy focuses on local outreach, awareness, and incentives to facilitate participation and addresses physical, fiscal, and psychological barriers.
Research suggests that reproductive factors, including number of children, miscarriages, age at first menstrual period, and reproductive period, may contribute to dementia risk in women. Women who had three or more children were found to have a lower risk of dementia, while those with earlier onset of menstruation or shorter reproducti...
The study found significant rates of depression, hypertension, stroke, and cardiovascular disease among sexual minority older adults, contributing to the level of dementia. The prevalence of dementia increases with age, even in 'oldest old', and survival time for people with dementia is six years regardless of age.
The recommendations aim to improve timely and accurate diagnosis of Alzheimer's disease by emphasizing a multidisciplinary evaluation approach. The guidelines also focus on compassionate communication with patients and caregivers, and establishing a structured assessment process.
A new $1.85 million grant will support a Phase 2 clinical trial of AMX0035, a combination of sodium phenylbutyrate and tauroursodeoxycholic-acid, to test its effectiveness in slowing or stopping brain cell death in people with mild cognitive impairment or Alzheimer's disease.
The Alzheimer's Association has launched a new initiative to explore potential sex differences in Alzheimer's disease. Emerging evidence suggests that biological or genetic differences may contribute to the higher frequency of Alzheimer's in women, and researchers will investigate hormone, genetics, and lifestyle factors. The goal is t...
The Alzheimer's Association has launched a $7 million challenge to accelerate Alzheimer's disease therapy, focusing on brain inflammation and the immune system. Four cutting-edge clinical trials will receive $1 million each to advance research, with the goal of unlocking new treatments for this devastating disease.
The Alzheimer's Association has awarded $4.3 million to accelerate the testing of new potential therapies and diagnostic approaches for Alzheimer's disease. The funding will support innovative trial designs, including tau PET imaging and home-based cognitive testing, to improve early detection and treatment options.
Researchers are developing a simple, inexpensive blood test that can detect the risk of Alzheimer's disease in individuals with Down syndrome. The test aims to identify people who will develop the disease before cognitive symptoms appear.
Ralph A. Nixon, a renowned neuroscientist, received the prestigious Zaven Khachaturian Award for his groundbreaking research on early brain changes associated with Alzheimer's disease. His work has helped scientists better understand the process of Alzheimer's development and progression.
Dr. Li Gan receives the Inge Grundke-Iqbal Award for her influential research on progranulin and amyloid accumulation in mouse models of Alzheimer's disease. Her work may protect against brain changes associated with the disease.
MetLife Foundation and GHR Foundation received the Jerome H. Stone Philanthropy Award for their significant investment in Alzheimer's research, totaling over $32 million. The awards recognize their impact on accelerating global efforts to eliminate Alzheimer's disease.
The Alzheimer's Association honored four leading scientists, including Alison Goate, Bengt Winblad, John Hodges, and Ian McKeith, for their groundbreaking research on Alzheimer's disease and dementia. The recognition aims to accelerate the global effort to eliminate Alzheimer's and advance research towards new treatments.
The Alzheimer's Association recognized MetLife Foundation and GHR Foundation for their significant investments in Alzheimer's research and public information programs. These foundations have supported over $32 million in research initiatives, including prevention studies and innovative approaches to Alzheimer's care.
A groundbreaking Alzheimer's disease prevention trial is supported by $10 million in new funding, focusing on therapies targeting amyloid proteins. The trial will test two investigational anti-amyloid therapies to prevent or delay Alzheimer's symptoms in people at high genetic risk.
The Alzheimer's Association has awarded nearly $4 million in new grants to support five Phase 1 and 2a clinical trials exploring innovative treatments for Alzheimer's disease. These grants will help bridge the gap in funding for early-phase clinical drug trials, supporting promising projects from academia and industry.
The Alzheimer's Association has awarded research grants to investigate non-drug treatments for Alzheimer's disease, including exercise and cognitive stimulation interventions. These studies aim to lower the risk of cognitive decline and dementia in older adults.
Research at the Alzheimer's Association International Conference 2014 found that participating in mentally stimulating activities and moderate physical exercise in middle age may help protect against Alzheimer's disease. Additionally, high blood pressure was seen to protect against cognitive decline in people aged 90 and older.
Research trials report associations between decreased odor identification and loss of brain cell function, as well as beta-amyloid buildup in the eye with progression to Alzheimer's. Early detection is crucial for intervention and prevention, with promising results suggesting potential methods for early detection in a research setting.
Dimebolin treatment causes an acute increase in brain beta amyloid levels, contradicting its potential as a clinically beneficial Alzheimer's drug. Despite this, the treatment still improves cognitive function in aged rodents and people suffering from mild to moderate Alzheimer's.
Researchers have identified a combination of brain imaging, memory tests, and protein analysis that can accurately diagnose early-stage Alzheimer's disease. The study used data from the ADNI initiative and found that combining these methods resulted in classification accuracy rates of up to 95.7%.
Researchers found that a 'heart healthy' diet, rich in whole grains, vegetables, low-fat dairy, and nuts, may slow cognitive decline. Ongoing moderate physical activity was also associated with improved cognitive function in older adults.
Two studies found a strong association between PTSD and increased Alzheimer's risk, but moderate alcohol consumption was shown to lower this risk. Adults also had limited knowledge about the relationship between heart health and brain health.
The Alzheimer's Association honored six researchers with lifetime achievement awards for their pioneering work in advancing Alzheimer's research. The awards acknowledged significant advancements in anti-dementia drug therapies and early detection, paving the way for defeating the disease.
Research shows a significant increase in people with Alzheimer's and dementia among the 'oldest old', aged 90+, in Europe. The prevalence of dementia standardized on the Italian population was 22.9%, with higher rates in women, increasing with advancing age.
A doctor's positive attitude to Alzheimer's diagnosis and their personal relationships with support services are powerful enablers for early diagnosis. However, barriers include differing health priorities, fear of damaging the doctor-patient relationship, and difficulties in referring patients to support services. GPs need education o...
A new study suggests that partnering with local physicians, conducting educational seminars, and utilizing community outreach are effective tools in recruiting people for Alzheimer's clinical studies. In contrast, patient registries and internet recruiting were found to be less successful strategies. The study also explores the importa...